ethyl (R)-8-((1-phenylethyl)amino)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate | 813445-18-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl (R)-8-((1-phenylethyl)amino)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate
• 英文别名: 8-((R)-1-phenyl-ethylamino)-1,4-dioxa-spiro[4.5]dec-7-ene-7-carboxylic acid ethyl ester；ethyl 8-((R)-1-phenylethylamino)-1,4-dioxaspiro[4.5]decane-7-carboxylate；ethyl 8-([(1R)-1-phenylethyl]amino)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate；(R)-ethyl 8-(1-phenylethylamino)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate；ethyl 8-[[(1R)-1-phenylethyl]amino]-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate
• CAS: 813445-18-0
• 化学式: C₁₉H₂₅NO₄
• 分子量: 331.412
• InChiKey: JKNWDBUVGKBOPK-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl (R)-8-((1-phenylethyl)amino)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 sodium hydroxide 作用下， 以 乙腈 、 二氯甲烷 、 水 为溶剂， 生成 ethyl (8R,9S)-8-[[(1R)-1-phenylethyl]amino]-1,4-dioxaspiro[4.5]decane-9-carboxylate
  参考文献：
  名称：

  N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

  摘要：

  本申请描述了化学式（I）的趋化因子受体活性调节剂或其药用盐形式，用于预防哮喘和其他过敏疾病，以及类风湿性关节炎和动脉粥样硬化等自身免疫病理的药物，包括其制备方法和中间体。

  公开号：

  US20040259914A1
• 作为产物：
  描述：

  1,4-环己二酮单乙二醇缩酮 在 ytterbium(III) triflate hydrate 、 sodium hydride 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 生成 ethyl (R)-8-((1-phenylethyl)amino)-1,4-dioxaspiro[4.5]dec-7-ene-7-carboxylate
  参考文献：
  名称：

  Preparation and biological evaluation of conformationally constrained BACE1 inhibitors

  摘要：

  The BACE1 enzyme is a key target for Alzheimer's disease. During our BACE1 research efforts, fragment screening revealed that bicyclic thiazine 3 had low millimolar activity against BACE1. Analysis of the co-crystal structure of 3 suggested that potency could be increased through extension toward the S3 pocket and through conformational constraint of the thiazine core. Pursuit of S3-binding groups produced low micromolar inhibitor 6, which informed the S3-design for constrained analogs 7 and 8, themselves prepared via independent, multi-step synthetic routes. Biological characterization of BACE inhibitors 6-8 is described. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.04.062

文献信息

• [EN] PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] DÉRIVÉS DE PIPÉRIDINE EN TANT QUE MODULATEURS D'ACTIVITÉ DE RÉCEPTEUR DE CHIMIOKINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009015166A1

  公开（公告）日：2009-01-29

  The present application describes modulators of MIP-1 of formula (I) : or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as set forth above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators are disclosed.

  本申请描述了公式（I）的MIP-1调节剂：或其立体异构体或药用可接受的盐，其中m、Q、T、W、Z、R1、R3、R4、R5、R5a和R5b如上所述。此外，还公开了利用这些调节剂治疗和预防哮喘和过敏性疾病等炎症性疾病，以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。
• Process of preparing N-ureidoalkyl-piperidines
  申请人：Carter H. Percy

  公开号：US20050277666A1

  公开（公告）日：2005-12-15

  The present application describes a process of preparing a compound of formula (IV), or salt or stereoisomer thereof: wherein Pg, at each occurrence, is independently selected from an amine protecting group; comprising the steps of reacting a compound of Formula with a reducing agent to give a compound of Formula III: reacting the compound of formula (III) with an amine of formula (IIa) using reductive amination to give the compound of formula (III)

  本申请描述了制备化合物IV的过程，或其盐或立体异构体：其中Pg在每次出现时独立地选择自氨基保护基团；包括以下步骤：将化合物Formula与还原剂反应得到化合物Formula III；将化合物Formula III与式IIa的胺基进行还原胺化反应得到化合物Formula III。
• N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
  申请人：——

  公开号：US20040259914A1

  公开（公告）日：2004-12-23

  The present application describes modulators of chemokine receptor activity of formula (I): 1 or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, including methods of preparing and intermediates thereof.

  本申请描述了化学式（I）的趋化因子受体活性调节剂或其药用盐形式，用于预防哮喘和其他过敏疾病，以及类风湿性关节炎和动脉粥样硬化等自身免疫病理的药物，包括其制备方法和中间体。
• DIHYDRO PYRROLOQUINOLINE DERIVATIVES
  申请人：Miura Kasei

  公开号：US20110112133A1

  公开（公告）日：2011-05-12

  A compound represented by the formula (I) wherein A is a benzene ring optionally having substituent(s), R is a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s), X1 and X2 are each a bond or a divalent C 1-5 chain hydrocarbon group optionally having substituent(s), X3 is a methylene group having substituent(s), Y is a bond or the like, and Z is a hydrocarbon group optionally having substituent(s) or the like, or a salt thereof. The compound of the present invention or a salt thereof is useful as an NK receptor antagonist.

  一种化合物的化学式为（I），其中A为苯环，可选有取代基；R为氢原子、一个烃基，可选有取代基，或一个杂环基，可选有取代基；X1和X2分别为键或一个双价的C1-5链烃基，可选有取代基；X3为一个具有取代基的亚甲基基团；Y为键或类似物；Z为一个烃基，可选有取代基或类似物，或其盐。本发明的化合物或其盐可用作NK受体拮抗剂。
• N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Ko Soo S.

  公开号：US20080132523A1

  公开（公告）日：2008-06-05

  The present application describes modulators of chemokine receptor activity of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, including methods of preparing and intermediates thereof.

  本申请描述了化学式（I）的趋化因子受体活性调节剂或其药学上可接受的盐形式，用于预防哮喘和其他过敏性疾病，以及自身免疫病理学，如类风湿性关节炎和动脉粥样硬化，包括其制备方法和中间体。